Active Ingredient History
Tumor-infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Renal Cell (Phase 1)
Colorectal Neoplasms (Phase 2)
Drug-Related Side Effects and Adverse Reactions (Early Phase 1)
Hamartoma (Phase 1)
Infections (Phase 1/Phase 2)
Kidney Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphocytes (Phase 1)
Lymphocytes, Tumor-Infiltrating (Early Phase 1)
Melanoma (Phase 3)
Multiple Myeloma (Phase 1/Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Skin Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
